News
In August 2025, Bayer announced a study of researchers will check the medical history and current medications of the participants. They will also perform a complete health check-up of all the ...
Pascal Soriot, Chief Executive Officer, AstraZeneca, said:. As we enter our next phase of growth, we have pledged $50 billion to continue to grow in the US, which includes the largest ...
Astrazeneca has announced a surge in revenue from cancer drugs amidst speculation that its boss is considering a listing in the US. The company reported an 11 per cent rise in total revenue to $28bn ...
Core operating profit increased by 13 per cent while pre-tax profit climbed by 26 per cent to $6.5bn. Pascal Soriot, chief executive at AstraZeneca, said: "Our strong momentum in revenue growth ...
Astrazeneca has revealed a jump in revenue from cancer drugs amid rumours its boos is eyeing a listing across the pond. Total revenue rose 11 per cent to $28bn (£12.98bn) in the first half of the year ...
AstraZeneca reported 11% year-on-year revenue growth, excluding a 1% currency headwind, and core operating profit growth of 14%. Management reiterated its full-year guidance of high single-digit ...
The project will establish a new manufacturing facility in the United States to develop drugs for weight loss, including oral GLP-1, baxdrostat, oral PCSK9, and combined low-molecular-weight drugs.
Six or 9 months of bedaquiline, delamanid, linezolid, and clofazimine was not noninferior to longer standard of care.
The cornerstone of this landmark investment is a new multi-billion-dollar US manufacturing facility that will produce drug substances for the company’s innovative weight management and metabolic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results